(Q36535928)

14 August 2017

Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate (English)

1 reference

14 August 2017

1 reference

1 reference

3

Matthew Links

1 reference

14 August 2017

2

Peter Galettis

1 reference

14 August 2017

Xuemin Jiang

1

1 reference

14 August 2017

Paul L Mitchell

series ordinal

4

1 reference

14 August 2017

Andrew J McLachlan

series ordinal

5

1 reference

14 August 2017

language of work or name

English

0 references

publication date

24 October 2007

1 reference

British Journal of Clinical Pharmacology

14 August 2017

1 reference

14 August 2017

65

1 reference

14 August 2017

3

1 reference

14 August 2017

326-333

1 reference

A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

A ten-year review of progress in the treatment of non-small-cell lung cancer with gemcitabine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

A review of systemic therapy for advanced pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Gemcitabine in metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Population pharmacokinetics: theory and practice

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study

28 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.03040.X

Assessment of actual significance levels for covariate effects in NONMEM.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.03040.X

Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2291243

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

21 September 2018

1 reference

12 December 2020

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

12 December 2020

Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer

1 reference

12 December 2020

10.1111/J.1365-2125.2007.03040.X

Identifiers

DOI

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

17961191

1 reference